An oral CCR9 antagonist (CCX282-B) is currently used in a Phase II clinical trial for the treatment of Crohn's disease and has shown efficacy in the treatment of patients with moderate to severe small bowel Crohn's disease [8]. The gene discussed is CCR9; the disease is small bowel Crohn disease.